Please join us in congratulating Dr. Ethel Cesarman on receiving a 2017 Daedalus Fund for Innovation Award of $223,000 over two years.
The WCM Daedalus Fund for Innovation is designed to support work needed to transit important basic science discoveries into industry alliances.
Dr. Cesarman’s laboratory has discovered a nucleoside analogue, 6-ETI, which has activity against malignancies that express adenosine kinase (ADK). Dr. Cesarman will use the support from this award to establish the efficacy of 6-ETI in treating pancreatic and colon adenocarcinoma in pre-clinical mouse models. Proven efficacy in these models will make 6-ETI an attractive licensing target.
Congratulations, Dr. Cesarman!